FIRST AIRED: December 5, 2018

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!

We've got more news

Get our editor’s daily email summary of what’s going on in the world.

US Edition
Intl. Edition
Replay Program
More Info

COMING UP:Share Opener Variant 4



>> $59 billion that's what it's costing Takeda pharmaceutical to join the ranks of top drug makers. The Japanese firm splashing all that cash on London listed Shire. It's the biggest ever overseas acquisition by a Japanese firm. The deal creates a global powerhouse with a strong list of new drugs.
But it also leaves Takeda saddled with enormous debts. The company taking out almost $31 billion in bank loans to finance the deal. That's been a big concern for shareholders. Takeda stocked down about a quarter in March when it first said it might buy Shire. Chief Executive Christophe Weber, undeterred though.
He says the combined firm will slash costs and sell $10 billion of non-core assets to pay down debt. Analysts generally agree Takeda needed to bulk up. But, they warn Japanese firms have a poor record when it comes to overseas acquisitions. Toshiba's decade of troubles and write down since by investing house just one of the quotient retails.